RVMD:NASDAQRevolution Medicines, Inc. Analysis
Data as of 2026-08-20 - not real-time
$211.74
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
At $211.74, Revolution Medicines, Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. It has gained 11.6% over the past 30 days. With RSI at 65.3 the momentum picture is approaching overbought, alongside a bullish MACD signal. Recent trading has carved out support near $178.07 and resistance around $220.34.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 4.8% above the current price.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 40.1%, a beta of 1.15 and a maximum drawdown of 25.0%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 4/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 4.8% above the current price.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 40.1%, a beta of 1.15 and a maximum drawdown of 25.0%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 4/10 long-term conviction.
Top Market Events
Revolution Medicines Inc RVMD reports paradigm-changing Phase 3 results and a robust $3.U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer...Two oncology powerhouses, BeOne Medicines AG NASDAQ:ONC and Revolution Medicines, Inc.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 125.18
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 125.18
- 30-day volatility of 40.1%
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Negative return on equity of -79.1%
- Negative free cash flow
- 30-day volatility of 40.1%
Key Metrics & Analysis
Financial Health
P/E Ratio-32.1
ROE-79.09%
ROA-30.12%
Debt/Equity45.68
P/B Ratio28.3
Op. Cash Flow$-1223032960
Free Cash Flow$-711607360
Industry P/E30.7
Technical Analysis
TrendBullish
RSI65.3
Support$178.07
Resistance$220.34
MA 20$197.95
MA 50$184.58
MA 200$125.18
MACDBullish
VolumeDecreasing
Fear & Greed Index92.84
Valuation
Target Price$221.90
Upside/Downside4.80%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.15
Volatility40.14%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.